CareDx, Inc. (CDNA)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
$50.03-0.56%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
Intact: The reason to own it still holds.
CareDx grows revenue about 10% a year to $456 million in 2026. The company is buying back $100 million of stock. The Naveris merger will help expand its business. Profitability is improving with steady earnings growth.
Growth could slow below 10% if new products or mergers fail. Profit margins may stay thin. Management changes could cause instability.
The price is about 4% below our fair value near $29. Analysts expect 11% revenue growth, close to our view.
Breaks if: Merger is not completed or significantly delayed
Close acquisition of Naveris, Inc. to strengthen position in precision medicine diagnostics.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CDNA represents a growth investment with a focus on increasing revenue and strategic mergers. The current thesis state is intact, with recent earnings beats contributing to positive sentiment.
The market appears to have a neutral view on CDNA's valuation, with a slight expectations gap indicating that some growth is already anticipated. The stock trades at a premium compared to peers, reflecting some confidence in its future performance.
Management is on track to increase revenue guidance, having recently raised expectations for the year. The company's recent financial performance has been strong, but there are elevated risks due to potential economic downturns.
The long-term thesis hinges on management's ability to maintain revenue growth and the impact of broader healthcare sector performance. Key factors include the performance of sector bellwethers and the potential for any negative guidance revisions.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Management announced the merger agreement with Naveris in 2026-Q1 and completed the acquisition by 2026-Q2. This strategic M&A activity is delivering as planned.
“Closed the acquisition of Naveris, strengthening CareDx’s position”
“Entered into an Agreement and Plan of Merger with Naveris, Inc.”
Breaks if: Revenue falls below $447 million in FY26
Raise full year 2026 revenue guidance reflecting strong growth in Testing Services and Patient and Digital Solutions.
Stated as a priority in 2 of last 2 quarters. Revenue grew 52% year-over-year to $132 million in 2026-Q2 from $87 million in 2025-Q2. Management raised full year 2026 revenue guidance twice, from $447M-$465M in 2026-Q1 to $490M-$500M in 2026-Q2. The trajectory is delivering with strong revenue growth and upward guidance revisions.
“Raises 2026 Revenue Guidance to $490 Million to $500 Million”
“Raises 2026 Revenue Guidance to $447 Million to $465 Million”
Breaks if: Buyback program is canceled or materially delayed
Implement a $100 million common stock repurchase program authorized in April 2026 to return capital to shareholders.
Stated as a priority in 2 of last 2 quarters. The Board authorized a $100 million stock repurchase program in April 2026, reiterated in Q2. No share buyback volumes reported yet, so delivery is pending but the capital allocation commitment is clear.
“Board authorized a common stock repurchase program of up to $100 million”
“Board authorized a common stock repurchase program of up to $100 million”
In the next 1 to 3 years, CDNA's performance will depend on its execution of growth strategies and external economic conditions. Not investment advice.